Literature DB >> 20177399

Emerging erythropoiesis-stimulating agents.

Robert N Foley1.   

Abstract

The stimulation of erythropoiesis is a rapidly evolving area of research, with mechanistic insights often developing rapidly into therapeutic agents. A broad range of erythropoiesis-stimulating agents are currently in clinical use and many more under development are likely to enter the marketplace in the near future. To date, much of the investigative activity in this field has targeted activation of the erythropoietin receptor and factors that modulate hypoxia-related pathways of erythropoietin production within cells. This Review discusses newer erythropoiesis-stimulating agents currently under assessment for the treatment of anemia in patients with chronic kidney disease. Such agents include proteins and peptides that activate erythropoietin receptors, non-protein agents, and strategies with targets other than erythropoietin receptors.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20177399     DOI： 10.1038/nrneph.2010.19

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


  66 in total

1.  Signal transduction. How do cells sense oxygen?

Authors:  H Zhu; H F Bunn
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

2.  Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.

Authors:  Yves Vanrenterghem; Peter Bárány; Johannes F E Mann; Peter G Kerr; Janet Wilson; Nigel F Baker; Stephen J Gray
Journal:  Kidney Int       Date:  2002-12       Impact factor: 10.612

3.  Small peptides as potent mimetics of the protein hormone erythropoietin.

Authors:  N C Wrighton; F X Farrell; R Chang; A K Kashyap; F P Barbone; L S Mulcahy; D L Johnson; R W Barrett; L K Jolliffe; W J Dower
Journal:  Science       Date:  1996-07-26       Impact factor: 47.728

4.  The first human cell line-derived erythropoietin, epoetin-delta (Dynepo), in the management of anemia in patients with chronic kidney disease.

Authors:  K J Martin
Journal:  Clin Nephrol       Date:  2007-07       Impact factor: 0.975

5.  C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks.

Authors:  Bruce Spinowitz; Daniel W Coyne; Charmaine E Lok; Mario Fraticelli; Maher Azer; Sanjay Dalal; Giuseppe Villa; Steven Rosansky; Helena Adamis; Ulrich Beyer
Journal:  Am J Nephrol       Date:  2007-11-13       Impact factor: 3.754

6.  Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.

Authors:  M Haag-Weber; A Vetter; U Thyroff-Friesinger
Journal:  Clin Nephrol       Date:  2009-11       Impact factor: 0.975

7.  A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia.

Authors:  Iain C Macdougall; Jerome Rossert; Nicole Casadevall; Richard B Stead; Anne-Marie Duliege; Marc Froissart; Kai-Uwe Eckardt
Journal:  N Engl J Med       Date:  2009-11-05       Impact factor: 91.245

8.  Epoetin delta in the management of renal anaemia: results of a 6-month study.

Authors:  Kevin J Martin
Journal:  Nephrol Dial Transplant       Date:  2007-07-27       Impact factor: 5.992

9.  The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects.

Authors:  T Salmonson; B G Danielson; B Wikström
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

10.  Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney.

Authors:  Chul Woo Yang; Can Li; Ju Young Jung; Seok Joon Shin; Bum Soon Choi; Sun Woo Lim; Bo Kyung Sun; Yong Soo Kim; Jin Kim; Yoon Sik Chang; Byung Kee Bang
Journal:  FASEB J       Date:  2003-07-18       Impact factor: 5.191
View more
  7 in total

1.  Effects of cobalt chloride on phenotypes of normal human saphenous vein smooth muscle cells.

Authors:  Jing Li; Huai-Ming Wang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Erythropoietin stimulation decreases hepcidin expression through hematopoietic activity on bone marrow cells in mice.

Authors:  Yusuke Sasaki; Mariko Noguchi-Sasaki; Hideyuki Yasuno; Keigo Yorozu; Yasushi Shimonaka
Journal:  Int J Hematol       Date:  2012-11-16       Impact factor: 2.490

3.  Epoetin beta pegol (C.E.R.A.) promotes utilization of iron for erythropoiesis through intensive suppression of serum hepcidin levels in mice.

Authors:  Yusuke Sasaki; Mariko Noguchi-Sasaki; Yukari Matsuo-Tezuka; Yuki Matsumoto-Omori; Mitsue Kurasawa; Keigo Yorozu; Yasushi Shimonaka
Journal:  Int J Hematol       Date:  2014-03-13       Impact factor: 2.490

4.  Bioinformatics Identification of Candidate Biomarkers in Endomyocardial Biopsy and Peripheral Blood for Cardiac Allograft Rejection.

Authors:  Kang Luo; Lin Li; Mingyao Meng; Yan Chen; Zongliu Hou
Journal:  Ann Transplant       Date:  2022-03-29       Impact factor: 1.530

Review 5.  Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients.

Authors:  Deirdre Hahn; June D Cody; Elisabeth M Hodson
Journal:  Cochrane Database Syst Rev       Date:  2014-05-28

6.  The effects of CoCl2 on HIF-1α protein under experimental conditions of autoprogressive hypoxia using mouse models.

Authors:  Yan-Bo Zhang; Xiulian Wang; Edward A Meister; Ke-Rui Gong; Shao-Chun Yan; Guo-Wei Lu; Xun-Ming Ji; Guo Shao
Journal:  Int J Mol Sci       Date:  2014-06-18       Impact factor: 5.923

Review 7.  A meta-analysis and systematic review evaluating the use of erythropoietin in total hip and knee arthroplasty.

Authors:  Yi Li; Pengbin Yin; Houchen Lv; Yutong Meng; Licheng Zhang; Peifu Tang
Journal:  Ther Clin Risk Manag       Date:  2018-07-10       Impact factor: 2.423
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.